Clinical Trials Logo

Urinary Bladder Neoplasms clinical trials

View clinical trials related to Urinary Bladder Neoplasms.

Filter by:

NCT ID: NCT03064308 Completed - Quality of Life Clinical Trials

The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery

POETold
Start date: June 26, 2017
Phase: N/A
Study type: Interventional

The primary aim of this study is to establish if it is possible for patients who have undergone major body surgery to complete a home based exercise training program and complete the assessments required to measure physical and cognitive function. If the investigators can establish that it is feasible to complete the training and test's then further research can follow using these methods to determine whether it is possible to improve the physical function of older patients undergoing major abdominal surgery in the period following surgery by using a simple exercise regimen that can be carried out at home. By targeting physical function in this way the investigators hope to determine if it is a method for improving frailty and well being. In turn it may also have a positive impact on health service provision.

NCT ID: NCT03063255 Completed - Cancer of Bladder Clinical Trials

Comparison of Obturator Nerve Blockade and Neuromuscular Blockade

Start date: April 25, 2017
Phase: Phase 4
Study type: Interventional

Patients diagnosed with posterolateral bladder tumors will be invited to participate in the study. Subjects will be randomized to receive an ultrasound-guided obturator block or a neuromuscular blocking agent after the induction of general anesthesia in an attempt to block the obturator reflex during surgery.

NCT ID: NCT03063125 Completed - Bladder Cancer Clinical Trials

Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer

Start date: March 31, 2017
Phase:
Study type: Observational

The purpose of this study is to examine the relationship between testosterone level changes around the time of radical cystectomy.

NCT ID: NCT03058757 Completed - Bladder Cancer Clinical Trials

The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation

Start date: February 1, 2017
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in non-muscle invasive bladder cancer patients

NCT ID: NCT03058705 Completed - Bladder Cancer Clinical Trials

Near Infrared Fluorescence Imaging for Bladder Cancer Detection

Start date: November 28, 2017
Phase: N/A
Study type: Interventional

The primary outcome of this study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate HCL avid tumors using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF).

NCT ID: NCT03053635 Completed - Clinical trials for Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG

Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients

Start date: December 21, 2016
Phase: Phase 1
Study type: Interventional

This is a phase Ib, open-label, single-arm, single-center study conducted in Canada. Subjects with NMIBC (Ta, T1, and/or Tis) who are not candidates for or have refused radical cystectomy will be eligible for participation in the study. Bacillus Calmette-Guerin (BCG) intolerance or refractory disease are defined as inability to tolerate or failure to achieve a tumour-free state after at least one induction (a minimum of 5 instillations) followed by either a second induction (a minimum of 5 instillations) or at least 2 maintenance instillations. Subjects experiencing disease relapse within 12 months or less after finishing the second course of BCG therapy are also considered refractory. The study will consist of 2 phases. In the first phase, 3 subjects will receive PDT (TLC-3200 System) employing 0.35 mg/cm^2 (maximum recommended starting dose) TLD1433. If treatment with the maximum recommended starting dose does not raise significant safety concerns as determined by the safety monitoring committee, an additional 6 subjects will receive PDT with 0.70 mg/cm^2 (therapeutic dose) TLD1433.

NCT ID: NCT03052504 Completed - Bladder Cancer Clinical Trials

Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy

Start date: September 2016
Phase:
Study type: Observational

The study will examine which differences there are in comorbidity and complications collected retrospectively from medical records compared with data collected prospectively in two groups of patients undergoing either radical cystectomy or radical nephrectomy. Hypothesis is that he prevalence of registered comorbidity and minor complications in patients who have undergone radical cystectomy or nephrectomy, will increase if the data collection is focused and prospective, compared with retrospectively collected data. The study will be conducted as a single-blind randomized controlled trial. Patients included in the study will be randomized to either control or intervention in the ratio 1:1. There are two groups of patients: Patients admitted to radical cystectomy and patients admitted to radical nephrectomy, due to cancer.

NCT ID: NCT03039543 Completed - Clinical trials for Neuromuscular Blockade

Neuromuscular Blockade During Transurethral Resection of Bladder Cancer

Start date: June 1, 2017
Phase: Phase 4
Study type: Interventional

Transurethral resection of the bladder tumor (TURB) for bladder tumor excision is the mainstream treatment. However, the beneficial effects of sugammadex after general anesthesia for TURB have not been thoroughly evaluated. Investigators hypothesized that deep NMB and the use of sugammadex as a reversal agent may be associated with better endoscopic surgical condition and recovery profile compared with moderate NMB during TURB. This study was designed to compare patients with deep neuromuscular blockade (NMB) with moderate NMB during transurethral resection of the bladder tumor (TURB) in terms of surgical condition and postoperative recovery.

NCT ID: NCT03029663 Completed - Bladder Cancer Clinical Trials

Complications of Transurethral Resection of the Bladder Tumour

ComTUR
Start date: December 2016
Phase:
Study type: Observational

This is a prospective study enrolling consecutive patients who undergo transurethral resection of the bladder tumour (TURBT) aimed at determination of a safety of the procedure. Study end-points are incidence, severity and predictive factors of surgical complications. The study secondary aim is a validation of Clavien Dindo scoring system for reporting complication of TURBT.

NCT ID: NCT03027284 Completed - Solid Tumor Clinical Trials

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Start date: February 3, 2017
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.